Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK T1151INST
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1. The crizotinib resistant clones were produced from parental H3122 cells (CR1, CR2, CR3). H3122 CR2 was found to contain the 1151 Tins variant as well as elevated EML4-ALK expression. H3122 CR2 cells treated with TAE684 produced IC50 values 20-30 times that of the parental H3122 cells. These results suggest possible variant resistance to the TAE684-derived compound ceritinib.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1348
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/173
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- TAE684
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 22277784
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| TAE684 | Resitance or Non-Reponse | true |